Crown Bioscience Recognized Once Again as T+ Employer® for the Third Year in a Row

SAN DIEGO–(BUSINESS WIRE)–Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, solidifies its stature as a frontrunner in the global healthcare sector by securing the T+ Employer® certification for healthcare excellence every year since the award was inaugurated in 2020. This prestigious accolade, awarded by the Health Human Resources Development Center … [Read more…]

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

LAFAYETTE, Colo.–(BUSINESS WIRE)–The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant … [Read more…]

QT Imaging Holdings names Dr. Raluca Dinu as Acting Chief Executive Officer and Anastas Budagov as Chief Financial Officer

NOVATO, Calif.–(BUSINESS WIRE)–QT Imaging Holdings, Inc. (NASDAQ:QTI) a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced that the Board of Directors has appointed former GigCapital5, Inc. CEO Dr. Raluca Dinu as Active Chief Executive Officer and member of the Board of Directors, effective March 12, 2024. Dr. … [Read more…]

Global Laboratory Glassware Washers Market Outlook & Forecast 2023-2028: A Shift from Manual to Automation in Laboratories – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Laboratory Glassware Washers Market – Outlook & Forecast 2023-2028” report has been added to ResearchAndMarkets.com’s offering. The global laboratory glassware washers market is expected to grow at a CAGR of 4.43% from 2022-2028. The global laboratory glassware washers market is an evolving market landscape that caters to the diverse needs of scientific … [Read more…]

Regence BlueCross BlueShield of Utah Welcomes Mike Woodruff, M.D., as Its Executive Medical Director

SALT LAKE CITY–(BUSINESS WIRE)–Regence BlueCross BlueShield of Utah welcomes Dr. Mike Woodruff as its new executive medical director. In this executive leadership role, he will drive clinical strategies focused on improving health care access, affordability, quality and member experience. Woodruff will oversee initiatives to promote provider partnerships, engage key employers in enhancing workforce well-being to … [Read more…]

Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

New analyses suggest REXULTI was associated with reductions in overall neuropsychiatric symptoms and in agitation symptoms REXULTI was associated with reductions in occupational disruptiveness/caregiver distress as early as four weeks Efficacy of REXULTI for agitation symptoms confirmed across dementia severity, care setting, concomitant/prior medication use, and co-occurring neuropsychiatric symptoms REXULTI was associated with improvement in … [Read more…]

Care Access Opens New Clinical Research Site in Warsaw, Poland

New clinical research site increases access to clinical trials in Poland and serves local communities and physicians in engaging with clinical research BOSTON–(BUSINESS WIRE)–#ClinicalResearch–Care Access, a global clinical research site company helping to accelerate the future of medicine, has opened its newest research site in Warsaw, Poland. The company’s expansion in Poland reinforces its commitment … [Read more…]

Shaperon Enrolls Its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy ‘Nugel’

210 Patients With Multi-Racial Atopic Dermatitis…Phase 2 Clinical Trial Begins CAMBRIDGE, Mass. & SEOUL, South Korea–(BUSINESS WIRE)–Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis. This milestone marks the start of a crucial … [Read more…]

Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

Dostarlimab-gxly plus chemotherapy is the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival (OS) in the overall population 31% reduction in risk of death and 16.4-month improvement in median OS observed with dostarlimab-gxly plus chemotherapy versus chemotherapy in the overall population 37% reduction in risk of disease progression or death and … [Read more…]

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion by the European Medicines Agency based on KarMMa-3 PRINCETON, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BMY #Abecma—Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) … [Read more…]